Elevated levels of soluble urokinase receptor in serum from mycobacteria infected patients: still looking for a marker of treatment efficacy

TY - CHAP

T1 - Elevated levels of soluble urokinase receptor in serum from mycobacteria infected patients

T2 - still looking for a marker of treatment efficacy

AU - Ostrowski, S R

AU - Ravn, P

AU - Hoyer-Hansen, G

AU - Ullum, H

AU - Andersen, A B

PY - 2006

Y1 - 2006

N2 - In search for a serological marker, which may be used to monitor treatment efficacy in patients with extra-pulmonary mycobacterial infections, serum samples were collected prospectively from patients during a 6-months treatment period. The levels of soluble urokinase-type plasminogen activator receptor (suPAR) and soluble tumour necrosis factor receptor II (sTNFrII) were measured and compared with erythrocyte sedimentation rate (SR) and C-reactive protein levels (CRP). sTNFrII levels were elevated at the time of diagnosis and declined in parallel with traditional inflammation markers (SR and CRP). suPAR levels were elevated to more than double (median 7.7 ng/ml, range 5.6-25.8) compared to levels previously reported for patients with pulmonary tuberculosis. The serum suPAR levels however remained high during the entire treatment period. This may reflect that significant inflammatory activity is continuing for more than 6 months in patients with extrapulmonary mycobacterial infections, despite adequate anti-tuberculosis treatment.

AB - In search for a serological marker, which may be used to monitor treatment efficacy in patients with extra-pulmonary mycobacterial infections, serum samples were collected prospectively from patients during a 6-months treatment period. The levels of soluble urokinase-type plasminogen activator receptor (suPAR) and soluble tumour necrosis factor receptor II (sTNFrII) were measured and compared with erythrocyte sedimentation rate (SR) and C-reactive protein levels (CRP). sTNFrII levels were elevated at the time of diagnosis and declined in parallel with traditional inflammation markers (SR and CRP). suPAR levels were elevated to more than double (median 7.7 ng/ml, range 5.6-25.8) compared to levels previously reported for patients with pulmonary tuberculosis. The serum suPAR levels however remained high during the entire treatment period. This may reflect that significant inflammatory activity is continuing for more than 6 months in patients with extrapulmonary mycobacterial infections, despite adequate anti-tuberculosis treatment.

KW - Adult

KW - Antitubercular Agents

KW - Biomarkers

KW - Colony Count, Microbial

KW - Endpoint Determination

KW - Female

KW - Humans

KW - Inflammation

KW - Male

KW - Mycobacterium tuberculosis

KW - Prospective Studies

KW - Receptors, Cell Surface

KW - Receptors, Urokinase Plasminogen Activator

KW - Treatment Outcome

KW - Tuberculosis, Pulmonary

KW - Evaluation Studies

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

U2 - 10.1080/00365540600868305

DO - 10.1080/00365540600868305

M3 - Book chapter

C2 - 17148072

VL - 38

T3 - Scandinavian Journal of Infectious Diseases. Supplementum

SP - 1028

EP - 1032

BT - Elevated levels of soluble urokinase receptor in serum from mycobacteria infected patients

ER -